Stocks › NTLA

Intellia Therapeutics, Inc.

NTLA·Nasdaq·United States United States·USD
$10.00
+0.48 (+5.04%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
NTLA
Intellia Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NTLAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of NTLA by members of U.S. Congress · 16 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Thomas R CarperThomas R CarperSenate · D · DE NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Sep 5, 2023 Aug 25, 2023 Filing ↗
Thomas R CarperThomas R CarperSenate · D · DE NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Jun 30, 2023 May 22, 2023 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$15,001 - $50,000
Mar 3, 2022 Feb 28, 2022 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Oct 30, 2021 Oct 29, 2021 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Oct 1, 2021 Sep 20, 2021 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Aug 7, 2021 Jul 21, 2021 Filing ↗
Thomas R CarperThomas R CarperSenate · D · DE NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
May 17, 2021 Nov 20, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Jan 31, 2021 Jan 15, 2021 Filing ↗
Thomas R CarperThomas R CarperSenate · D · DE NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Dec 2, 2020 Nov 20, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Dec 1, 2020 Nov 18, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Sale
$1,001 - $15,000
Sep 6, 2020 Aug 26, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Aug 9, 2020 Jul 10, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Feb 22, 2020 Jan 14, 2020 Filing ↗
Donald S. Beyer, Jr.Donald S. Beyer, Jr.House · D · VA NTLAIntellia Therapeutics, Inc. · Stock Purchase
$1,001 - $15,000
Dec 14, 2019 Dec 9, 2019 Filing ↗
James M InhofeJames M InhofeSenate · R · OK NTLAIntellia Therapeutics, Inc. · Stock Sale
$15,001 - $50,000
Nov 8, 2018 Oct 25, 2018 Filing ↗
James M InhofeJames M InhofeSenate · R · OK NTLAIntellia Therapeutics, Inc. · Stock Purchase
$15,001 - $50,000
Nov 8, 2017 Oct 19, 2017 Filing ↗

Whale Activity

Position changes in NTLA reported for 2026-09-30 by 359 institutional filers
Increased: 116New: 30Held: 60Decreased: 91Closed: 47No prior filing: 15
  • Increased116
  • New30
  • Held60
  • Decreased91
  • Closed47
  • No prior filing15
FilerSharesValueChange
BlackRock, Inc.16.0M$193.4Mincreased
ARK Investment Management LLC15.9M$192.1Mdecreased
STATE STREET CORP7.8M$94.2Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC7.4M$89.1Mincreased
D. E. Shaw & Co., Inc.6.1M$73.1Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC6.0M$72.9Mincreased
TWO SIGMA INVESTMENTS, LP4.7M$56.8Mdecreased
FMR LLC4.7M$56.6Mdecreased
REGENERON PHARMACEUTICALS, INC.3.7M$44.7Mheld
Amova Asset Management Americas, Inc.3.6M$43.5Mincreased
Sumitomo Mitsui Trust Group, Inc.3.6M$43.5Mincreased
GEODE CAPITAL MANAGEMENT, LLC3.5M$42.1Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by NTLA insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: -71.8K2025 Q12025 Q2: -1,8122025 Q22025 Q3: 87.5K2025 Q32025 Q4: -90.0K2025 Q42026 Q1: 64.3K2026 Q12026 Q2: 02026 Q22026 Q3: -38.1K2026 Q32026 Q4: -10.9K2026 Q4

Recent Insider Transactions

517 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
LEONARD JOHN MPresident and CEO · Director Sale −9,000 $11.99 $108K Nov 2, 2026 Form 4 ↗
Dube Michael PVP, Chief Accounting Officer Sale −1,864 $12.43 $23K Oct 2, 2026 Form 4 ↗
LEONARD JOHN MPresident and CEO · Director Sale −2,785 $13.00 $36K Aug 21, 2026 Form 4 ↗
LEONARD JOHN MPresident and CEO · Director Sale −19.9K $12.60 $251K Aug 20, 2026 Form 4 ↗
Dulac Edward J IIIEVP, Chief Financial Officer Sale −8,111 $11.25 $91K Jul 22, 2026 Form 4 ↗
Dulac Edward J IIIEVP, Chief Financial Officer Sale −4,677 $18.00 $84K Jul 2, 2026 Form 4 ↗
Dube Michael PVP, Chief Accounting Officer Sale −2,641 $16.78 $44K Jul 1, 2026 Form 4 ↗
GOODMAN JESSEDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
CHASE WILLIAM JDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
Verwiel FrankDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
Keresty GeorgiaDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
Goff BrianDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
Cohen Fred EDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
Bhanji MunaDirector Grant / award +9,200 $0.00 $0 Jun 9, 2026 Form 4 ↗
BASTA JAMESEVP, General Counsel Sale −1,211 $13.78 $17K Mar 2, 2026 Form 4 ↗
Clark ElianaEVP, Chief Technical Officer Sale −607 $13.78 $8K Mar 2, 2026 Form 4 ↗
LEONARD JOHN MPresident and CEO · Director Grant / award +156.4K $0.00 $0 Mar 1, 2026 Form 4 ↗
BASTA JAMESEVP, General Counsel Grant / award +46.1K $0.00 $0 Mar 1, 2026 Form 4 ↗
Lebwohl DavidEVP, Chief Medical Officer Grant / award +9,943 $0.00 $0 Mar 1, 2026 Form 4 ↗
Dulac Edward J IIIEVP, Chief Financial Officer Grant / award +61.3K $0.00 $0 Mar 1, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding NTLA · SEC Form N-PORT
FundSharesValue% of fundAs of
ARK Innovation ETF
ARK ETF Trust
10.0M$106.7M1.92%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
5.8M$97.4M0.91%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.3M$72.5M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.5M$59.6M0.07%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.1M$52.6M0.03%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.8M$30.4M0.06%Jun 30, 2026
ARK Genomic Revolution ETF
ARK ETF Trust
2.7M$28.5M1.83%Jul 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.6M$27.2M0.03%Jun 30, 2026
Select Biotechnology Portfolio
Fidelity Select Portfolios
1.9M$24.4M0.39%Aug 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
1.3M$21.4M0.15%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list NTLA's shares (CUSIP 45826J105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.8M shares5.6%
    Nov 10, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 9.2M shares6.8%
    Aug 7, 2026 · ↗
  • GOLDMAN SACHS & CO. LLCSCHEDULE 13G · passive (13G) · 5.5M shares5.1%
    Nov 12, 2025 · ↗
  • THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G · passive (13G) · 5.5M shares5.1%
    Nov 12, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming intellia therapeutics as client

No lobbying filings found naming Intellia Therapeutics, Inc. as the client.

  • CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
    Filing ↗
  • CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
    Filing ↗
  • CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q4 · HCR$30K
    Filing ↗
  • CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q3 · HCR$30K
    Filing ↗
  • CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q2 · HCR$30K
    Filing ↗

Government Contracts

Federal awards to Intellia Therapeutics, Inc. · USAspending

No federal contract awards found for Intellia Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Intellia Therapeutics, Inc.

No USPTO patent applications found for Intellia Therapeutics, Inc..

Annual Financials

From NTLA's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$67.7M$57.9M$36.3M$52.1M$33.1M
Operating income-$441.0M-$534.3M-$515.3M-$458.2M-$267.9M
Net income-$412.7M-$519.0M-$481.2M-$474.2M-$267.9M
Diluted EPS-$3.81-$5.25-$5.42-$6.16-$3.78
Operating cash flow-$394.7M-$348.9M-$394.1M-$333.3M-$225.0M
Cash and equivalents$155.5M$189.2M$226.7M$523.5M$123.4M
Total assets$842.1M$1.19B$1.30B$1.52B$1.29B
Total liabilities$170.7M$319.1M$250.8M$284.5Mn/a
Shareholders' equity$671.4M$872.0M$1.05B$1.24B$1.04B

As Intellia Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in NTLA's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K/A · Items 7.01, 9.01Reg FD disclosureNov 13, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 7.01, 9.01Material agreement · Direct financial obligation · Reg FD disclosureSep 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 10, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
    EDGAR ↗

About Intellia Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2835)In Vitro & In Vivo Diagnostic Substances
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE